Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer

Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We studied whether testosterone and AR signalling interferes with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mout, Lisanne, Moll, Jan M., Chen, Mingqing, de Morrée, Eleonora S., de Ridder, Corrina M. A., Gibson, Alice, Stuurman, Debra, Aghai, Ashraf, Erkens-Schulze, Sigrun, Mathijssen, Ron H. J., Sparreboom, Alex, de Wit, Ronald, Lolkema, Martijn P., van Weerden, Wytske M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722857/
https://www.ncbi.nlm.nih.gov/pubmed/32989230
http://dx.doi.org/10.1038/s41416-020-01105-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722857/
https://www.ncbi.nlm.nih.gov/pubmed/32989230
http://dx.doi.org/10.1038/s41416-020-01105-y

Ejemplares similares